Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).

Elamin YY, Gomez DR, Antonoff MB, Robichaux JP, Tran H, Shorter MK, Bohac JM, Negrao MV, Le X, Rinsurogkawong W, Lewis J, Lacerda L, Roarty EB, Swisher SG, Roth JA, Zhang J, Papadimitrakopoulou V, Heymach JV.

Clin Lung Cancer. 2019 Jan;20(1):43-47. doi: 10.1016/j.cllc.2018.09.015. Epub 2018 Sep 24.

PMID:
30343004
2.

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.

Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV.

Clin Cancer Res. 2018 Dec 15;24(24):6195-6203. doi: 10.1158/1078-0432.CCR-18-1542. Epub 2018 Sep 18.

PMID:
30228210
3.

Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.

Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, Roarty EB, Lacerda L, Swisher S, Heymach JV, Fossella FV, William WN.

Lung Cancer. 2017 Oct;112:90-95. doi: 10.1016/j.lungcan.2017.07.034. Epub 2017 Aug 3.

PMID:
29191606
4.

Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism.

Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, Ueno NT, Gilcrease M, Woodward WA.

Oncotarget. 2016 May 10;7(19):28329-39. doi: 10.18632/oncotarget.8631.

5.

miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer.

Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Wu W, Calin GA, Krishnamurthy S, Zhang XH, Buchholz TA, Ueno NT, Reuben JM, Woodward WA.

J Natl Cancer Inst. 2016 Apr 13;108(8). doi: 10.1093/jnci/djw026. Print 2016 Aug.

6.

Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.

Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA.

Breast Cancer Res Treat. 2015 Dec;154(3):495-508. doi: 10.1007/s10549-015-3645-3. Epub 2015 Nov 21.

7.

Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model.

Lacerda L, Debeb BG, Smith D, Larson R, Solley T, Xu W, Krishnamurthy S, Gong Y, Levy LB, Buchholz T, Ueno NT, Klopp A, Woodward WA.

Breast Cancer Res. 2015 Mar 20;17:42. doi: 10.1186/s13058-015-0549-4.

8.

Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.

Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA.

Stem Cells Transl Med. 2014 Jul;3(7):849-56. doi: 10.5966/sctm.2013-0204. Epub 2014 May 15.

9.

How do functionalized carbon nanotubes land on, bind to and pierce through model and plasma membranes.

Lacerda L, Ali-Boucetta H, Kraszewski S, Tarek M, Prato M, Ramseyer C, Kostarelos K, Bianco A.

Nanoscale. 2013 Nov 7;5(21):10242-50. doi: 10.1039/c3nr03184e. Epub 2013 Sep 5.

PMID:
24056765
10.

The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer.

Xu W, Lacerda L, Debeb BG, Atkinson RL, Solley TN, Li L, Orton D, McMurray JS, Hang BI, Lee E, Klopp AH, Ueno NT, Reuben JM, Krishnamurthy S, Woodward WA.

PLoS One. 2013 Aug 27;8(8):e71508. doi: 10.1371/journal.pone.0071508. eCollection 2013.

11.

Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling.

Debeb BG, Lacerda L, Xu W, Larson R, Solley T, Atkinson R, Sulman EP, Ueno NT, Krishnamurthy S, Reuben JM, Buchholz TA, Woodward WA.

Stem Cells. 2012 Nov;30(11):2366-77. doi: 10.1002/stem.1219.

12.

Translocation mechanisms of chemically functionalised carbon nanotubes across plasma membranes.

Lacerda L, Russier J, Pastorin G, Herrero MA, Venturelli E, Dumortier H, Al-Jamal KT, Prato M, Kostarelos K, Bianco A.

Biomaterials. 2012 Apr;33(11):3334-43. doi: 10.1016/j.biomaterials.2012.01.024. Epub 2012 Jan 30.

PMID:
22289266
13.

Tetrandrine, a Compound Common in Chinese Traditional Medicine, Preferentially Kills Breast Cancer Tumor Initiating Cells (TICs) In Vitro.

Xu W, Debeb BG, Lacerda L, Li J, Woodward WA.

Cancers (Basel). 2011 May 4;3(2):2274-85. doi: 10.3390/cancers3022274.

14.

Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells.

Klopp AH, Lacerda L, Gupta A, Debeb BG, Solley T, Li L, Spaeth E, Xu W, Zhang X, Lewis MT, Reuben JM, Krishnamurthy S, Ferrari M, Gaspar R, Buchholz TA, Cristofanilli M, Marini F, Andreeff M, Woodward WA.

PLoS One. 2010 Aug 16;5(8):e12180. doi: 10.1371/journal.pone.0012180.

15.

The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches.

Lacerda L, Pusztai L, Woodward WA.

Drug Resist Updat. 2010 Aug-Oct;13(4-5):99-108. doi: 10.1016/j.drup.2010.08.001. Epub 2010 Aug 23. Review.

PMID:
20739212
16.

Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells.

Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA.

Mol Cancer. 2010 Jul 8;9:180. doi: 10.1186/1476-4598-9-180.

17.

Potential targets for improving radiosensitivity of breast tumor-initiating cells.

Xu W, Debeb BG, Lacerda L, Woodward WA.

Anticancer Agents Med Chem. 2010 Feb;10(2):152-6. Review.

PMID:
20184537
18.

Lipid-quantum dot bilayer vesicles enhance tumor cell uptake and retention in vitro and in vivo.

Al-Jamal WT, Al-Jamal KT, Tian B, Lacerda L, Bomans PH, Frederik PM, Kostarelos K.

ACS Nano. 2008 Mar;2(3):408-18. doi: 10.1021/nn700176a.

PMID:
19206564
19.

Nanoengineering artificial lipid envelopes around adenovirus by self-assembly.

Singh R, Al-Jamal KT, Lacerda L, Kostarelos K.

ACS Nano. 2008 May;2(5):1040-50. doi: 10.1021/nn8000565.

PMID:
19206502
20.

Carbon-nanotube shape and individualization critical for renal excretion.

Lacerda L, Herrero MA, Venner K, Bianco A, Prato M, Kostarelos K.

Small. 2008 Aug;4(8):1130-2. doi: 10.1002/smll.200800323. No abstract available.

PMID:
18666166

Supplemental Content

Loading ...
Support Center